ABMD - Abiomed wins FDA approval for Impella heart pump

jayk7/Moment via Getty Images Abiomed (ABMD) announced that the FDA issued the pre-market approval ((PMA)) for the right heart pump, the Impella RP with SmartAssist as a potential treatment of acute right heart failure for up to 14 days. “Impella RP with SmartAssist further improves an incredibly valuable tool to treat right heart dysfunction,” commented Robert Salazar, an interventional cardiologist. “The addition of SmartAssist technology to Impella RP is an important advancement to help physicians achieve even better patient outcomes with an improved design and intuitive metrics.” In June 2020, the FDA granted an emergency use authorization ((EUA)) for Impella RP as a treatment for patients suffering from COVID-19-related right heart failure or decompensation. In June, Abiomed announced the acquisition of preCARDIA, a company focused on treatments for patients with acute heart failure.

For further details see:

Abiomed wins FDA approval for Impella heart pump